G-351 Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Provides a Sustained 48-Week Response, Reducing Serum Uric Acid and Preserving Renal Function in Patients With Uncontrolled Gout (UG) and Stage 3 Chronic Kidney Disease